24.96

1.55% 0.38

Catalyst Pharmaceuticals Inc (CPRX)

Overview News Price History Option Chain Financials Why CPRX Down? Discussions Forecast

Catalyst Pharmaceuticals Inc stock is traded at $24.96, with a volume of 2.08M. It is up +1.55% in the last 24 hours and up +2.80% over the past month. Catalyst Pharmaceuticals Inc is a biopharmaceutical company. It focuses on developing and commercializing, developing therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. It offers three drug products, FIRDAPSE (amifampridine), FYCOMPA (perampanel), and AGAMREE (vamorolone).

Previous Close:

$24.58

Open:

$24.61

24h Volume:

2.08M

Relative Volume:

1.67

Market Cap:

$3.04B

Revenue:

$460.48M

Net Income/Loss:

$142.80M

P/E Ratio:

21.15

EPS:

1.18

Net Cash Flow:

$221.79M

1W Performance:

+1.92%

1M Performance:

+2.80%

6M Performance:

+13.09%

1Y Performance:

+54.93%

1-Day Range:

$24.18

$25.23

1-Week Range:

$24.18

$25.23

52-Week Range:

$14.75

$26.16

Catalyst Pharmaceuticals Inc Stock (CPRX) Company Profile

Name

Catalyst Pharmaceuticals Inc

Sector

Healthcare (1170)

Industry

Biotechnology (667)

Phone

(305) 529-2522

Address

355 ALHAMBRA CIRCLE, CORAL GABLES

Employee

167

Twitter

@CatalystForRare

Next Earnings Date

2024-11-06

Latest SEC Filings

CPRX's Discussions on Twitter

Compare CPRX with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
CPRX Catalyst Pharmaceuticals Inc	24.96	2.99B	460.48M	142.80M	221.79M	1.18
ONC Beone Medicines Ltd Adr	245.58	26.10B	3.81B	-644.79M	-669.77M	-6.24
VRTX Vertex Pharmaceuticals Inc	442.05	111.96B	11.10B	-988.90M	-1.26B	-3.92
AKTX Akari Therapeutics Plc Adr	1.35	42.96M	0	0	0	0.00
VRNA Verona Pharma Plc Adr	81.20	6.39B	0	-153.72M	-103.81M	-2.00
REGN Regeneron Pharmaceuticals Inc	490.28	63.52B	14.09B	4.50B	2.96B	39.28

Catalyst Pharmaceuticals Inc Stock (CPRX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-04-25	Initiated	Robert W. Baird	Outperform
Nov-18-24	Initiated	Stephens	Overweight
Mar-14-24	Initiated	Citigroup	Buy
Mar-07-24	Initiated	BofA Securities	Buy
Dec-21-23	Initiated	Oppenheimer	Outperform
Aug-24-22	Downgrade	ROTH Capital	Buy → Neutral
Sep-21-18	Initiated	Cantor Fitzgerald	Overweight
Sep-07-18	Resumed	Piper Jaffray	Overweight
Oct-05-16	Upgrade	Piper Jaffray	Neutral → Overweight
Apr-26-16	Downgrade	Piper Jaffray	Overweight → Neutral
Sep-30-14	Reiterated	ROTH Capital	Buy
Sep-16-14	Reiterated	ROTH Capital	Buy
Sep-15-14	Reiterated	H.C. Wainwright	Buy
Oct-21-13	Reiterated	Aegis Capital	Buy
Sep-24-13	Initiated	Maxim Group	Buy
Sep-06-13	Reiterated	Aegis Capital	Buy
Apr-18-13	Initiated	Aegis Capital	Buy
Aug-27-12	Upgrade	Rodman & Renshaw	Mkt Perform → Mkt Outperform
Oct-01-09	Upgrade	Merriman	Sell → Neutral
May-29-09	Downgrade	Hapoalim	Neutral → Underperform
May-29-09	Downgrade	Merriman Curhan Ford	Buy → Sell
Dec-15-08	Initiated	Merriman Curhan Ford	Buy
Nov-28-07	Initiated	Rodman & Renshaw	Mkt Outperform
Jan-31-07	Initiated	Stifel Nicolaus	Buy
Jan-05-07	Initiated	First Albany	Buy

View All

Catalyst Pharmaceuticals Inc Stock (CPRX) Latest News

03:14 AM

(CPRX) Trading Report - news.stocktradersdaily.com

03:14 AM

May 31, 2025

Catalyst: Solid Business Model Propels Growth For This Buy And Build Pharma (NASDAQ:CPRX) - Seeking Alpha

May 31, 2025

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Receives Consensus Recommendation of “Buy” from Brokerages - Defense World

May 31, 2025

Zacks Research Brokers Raise Earnings Estimates for CPRX - Defense World

May 31, 2025

May 30, 2025

Catalyst Pharmaceuticals, Inc.'s (NASDAQ:CPRX) Earnings Are Not Doing Enough For Some Investors - simplywall.st

May 30, 2025

May 27, 2025

ProShare Advisors LLC Boosts Stock Position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - MarketBeat

May 27, 2025

D. E. Shaw & Co. Inc. Buys Shares of 18,173 Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - Defense World

May 27, 2025

May 25, 2025

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Position Decreased by Jane Street Group LLC - Defense World

May 25, 2025

May 24, 2025

Cetera Investment Advisers Grows Holdings in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - Defense World

May 24, 2025

Ameriprise Financial Inc. Grows Stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - Defense World

May 24, 2025

May 20, 2025

Transcript : Catalyst Pharmaceuticals, Inc.Shareholder/Analyst Call - marketscreener.com

May 20, 2025

May 14, 2025

Catalyst Pharmaceuticals at Bank of America 2025: Strategic Expansion and Growth - Investing.com Canada

May 14, 2025

Transcript : Catalyst Pharmaceuticals, Inc. Presents at BofA Securities 2025 Healthcare Conference, May-14-2025 08 - marketscreener.com

May 14, 2025

The Strong Earnings Posted By Catalyst Pharmaceuticals (NASDAQ:CPRX) Are A Good Indication Of The Strength Of The Business - Yahoo Finance

May 14, 2025

May 11, 2025

Catalyst pharmaceuticals reaffirms 2025 revenue guidance of $545M-$565M with strong FIRDAPSE and AGAMREE performance - MSN

May 11, 2025

(CPRX) Trading Signals - news.stocktradersdaily.com

May 11, 2025

Catalyst Pharmaceuticals Q1 Earnings Beat, Firdapse Revenues Rise Y/Y - MSN

May 11, 2025

May 09, 2025

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Q1 2025 Earnings Call Transcript - Insider Monkey

May 09, 2025

Catalyst Pharmaceuticals Reports Record Q1 2025 Results - TipRanks

May 09, 2025